Page last updated: 2024-08-05 13:11:48
imidazopyrazine
null
ChEBI ID: 37847
Members (3)
Member | Definition | Role |
---|---|---|
3-methyl-4,7-bis(methylsulfonyl)-3a,5,6,7a-tetrahydro-1H-imidazo[4,5-b]pyrazin-2-one | 3-methyl-4,7-bis(methylsulfonyl)-3a,5,6,7a-tetrahydro-1H-imidazo[4,5-b]pyrazin-2-one | |
5,6-dichloro-1H-imidazo[4,5-b]pyrazine-2-carboxylic acid | 5,6-dichloro-1H-imidazo[4,5-b]pyrazine-2-carboxylic acid | |
acp-196 | A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. | acalabrutinib |
Research
Studies (218)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (0.46) | 29.6817 |
2010's | 62 (28.44) | 24.3611 |
2020's | 155 (71.10) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 39 (17.18%) | 5.53% |
Reviews | 50 (22.03%) | 6.00% |
Case Studies | 9 (3.96%) | 4.05% |
Observational | 1 (0.44%) | 0.25% |
Other | 128 (56.39%) | 84.16% |